PCA3 Score Before Radical Prostatectomy Predicts Extracapsular Extension and Tumor Volume

Journal of Urology

Volumn 180, Issue 5, 2008, Pages 1975-1979

  Whitman, Eric J ^a   Groskopf, Jack ^a   Ali, Amina ^a   Chen, Yongmei ^a   Blase, Amy ^a   Furusato, Bungo ^a   Petrovics, Gyorgy ^a   Ibrahim, Mona ^a   Elsamanoudi, Sally ^a   Cullen, Jennifer ^a   Sesterhenn, Isabell A ^a   Brassell, Stephen ^a   Rittenhouse, Harry ^a   Srivastava, Shiv ^a   McLeod, David G ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

gene expression; prostate; prostatic neoplasms; tumor marker, biological; urine

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; PROTEIN PCA3; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME; URINALYSIS;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIGENS, NEOPLASM; BIOPSY, NEEDLE; COHORT STUDIES; DIGITAL RECTAL EXAMINATION; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROBABILITY; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RNA, MESSENGER; ROC CURVE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 53449088140     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.07.060     Document Type: Article

References (20)

1. D'Amico A.V., Whittington R., Malkowicz S.B., Fondurulia J., Chen M.H., Kaplan I., et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 17 (1999) 168
2. Kattan M.W., Cuzick J., Fisher G., Berney D.M., Oliver T., Foster C.S., et al. Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer 112 (2008) 69
3. Makarov D.V., Trock B.J., Humphreys E.B., Mangold L.A., Walsh P.C., Epstein J.I., et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69 (2007) 1095
4. Dong F., Jones J.S., Stephenson A.J., Magi-Galluzzi C., Reuther A.M., and Klein E.A. Prostate cancer volume at biopsy predicts clinically significant upgrading. J Urol 179 (2008) 896
5. Tavangar S., Razi A., and Mashayekhi R. Correlation between prostate needle biopsy and radical prostatectomy Gleason gradings of 111 cases with prostatic adenocarcinoma. Urol J 1 (2004) 246
6. Roemeling S., Roobol M.J., Postma R., Gosselaar C., van derKwast T.H., Bangma C.H., et al. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol 50 (2006) 475
7. Cairns P., Esteller M., Herman J.G., Schoenberg M., Jeronimo C., Sanchez-Cespedes M., et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 7 (2001) 2727
8. Ochiai A., Shukla A., Davis J.W., Fritsche H.A., Bhadkamkar V., and Babaian R.J. Is there a role for serum human tissue kallikrein in detection of prostate cancer?. Urology 70 (2007) 519
9. Parekh D.J., Ankerst D.P., Troyer D., Srivastava S., and Thompson I.M. Biomarkers for prostate cancer detection. J Urol 178 (2007) 2252
10. Hessels D., Klein Gunnewiek J.M., van Oort I., Karthaus H.F., van Leenders G.J., van Balken B., et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44 (2003) 8
11. Deras I.L., Aubin S.M., Blase A., Day J.R., Koo S., Partin A.W., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179 (2008) 1587
12. Marks L.S., Fradet Y., Deras I.L., Blase A., Mathis J., Aubin S.M., et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69 (2007) 532
13. Petrovics G., Liu A., Shaheduzzaman S., Furusato B., Sun C., Chen Y., et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24 (2005) 3847
14. Bussemakers M.J., van Bokhoven A., Verhaegh G.W., Smit F.P., Karthaus H.F., Schalken J.A., et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59 (1999) 5975
15. de Kok J.B., Verhaegh G.W., Roelofs R.W., Hessels D., Kiemeney L.A., Aalders T.W., et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62 (2002) 2695
16. Groskopf J., Aubin S.M., Deras I.L., Blase A., Bodrug S., Clark C., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52 (2006) 1089
17. Nakanishi H., Groskopf J., Fritsche H., Bhadkamkar V., Blase A., Kumar S., et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 179 (2008) 1804
18. Furusato B., Gao C.L., Ravindranath L., Chen Y., Cullen J., McLeod D.G., et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 21 (2008) 67
19. Chen M.E., Johnston D., Reyes A.O., Soto C.P., Babaian R.J., and Troncoso P. A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol 27 (2003) 1291
20. Freedman M.L., Haiman C.A., Patterson N., McDonald G.J., Tandon A., Waliszewska A., et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci USA 103 (2006) 14068